US 9,809,589 B2
Crystal form of compound used as mineralocorticoid receptor antagonist and preparation method therefor
Chen Jiang, Jinan (CN); Aichen Wang, Jinan (CN); and Dedong Zhang, Jinan (CN)
Assigned to KBP BIOSCIENCES CO., LTD., Jinan, Shandong Province (CN)
Appl. No. 14/653,933
Filed by KBP BIOSCIENCES CO., LTD., Jinan, Shandong (CN)
PCT Filed Dec. 23, 2013, PCT No. PCT/CN2013/090252
§ 371(c)(1), (2) Date Jun. 19, 2015,
PCT Pub. No. WO2014/094664, PCT Pub. Date Jun. 26, 2014.
Claims priority of application No. 2012 1 0563636 (CN), filed on Dec. 22, 2012.
Prior Publication US 2015/0336950 A1, Nov. 26, 2015
Int. Cl. C07D 471/04 (2006.01); C07D 215/20 (2006.01); C07D 215/60 (2006.01); C07D 215/48 (2006.01); C07C 255/50 (2006.01)
CPC C07D 471/04 (2013.01) [C07C 255/50 (2013.01); C07D 215/20 (2013.01); C07D 215/48 (2013.01); C07D 215/60 (2013.01)] 16 Claims
 
1. A crystal form of a compound represented by formula (1), 2-chloro-4-[(3S,3aR)-3-cyclopentyl-7-(4-hydroxypiperidin-1-carbonyl)-3,3a,4,5-tetrahydro-2H-pyrazolo[3,4-f]quinolin-2-yl]benzonitrile, which is obtainable from subjecting (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-pyrazolo[3,4-f]quinoline-7-carboxylic acid and 4-hydroxypiperidine to a condensation reaction,

OG Complex Work Unit Drawing
which is characterized by having an X-ray powder diffraction pattern comprising the following characteristic peaks expressed by 2θ degree, when measured using CuKa radiation:
Crystal Form I: 9.8°±0.2°, 12.9°±0.2°, 14.8°±0.2°, 15.4°±0.2°, 16.9°±0.2°, 17.4°±0.2°, 19.4°±0.2°, 19.8°±0.2°, 22.6°±0.2°, 26.2°±0.2°;
Crystal Form II: 4.5°±0.2°, 9.0°±0.2°, 12.2°±0.2°, 14.0°±0.2°, 14.6°±0.2°, 18.0°±0.2°, 18.7°±0.2°, 19.9°±0.2°, 21.2°±0.2°, 24.6°±0.2°.